Providers, payers, and health systems need to catch up, said Melanie Thompson, M.D., at the ACTHIV conference.
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.
The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
Word is getting out that, barring some major setback, long-acting injectable HIV antiretrovirals will soon be coming our way. Patients have come to my clinic asking about it; others muse that they wish there were shots instead of pills, and are heart...
As unsavory as probably it is to most of us, there's big news in the claim by He Jiankui, Ph.D., that he was able to use Crispr-Cas9 technology to alter the genes of twin girls so they were born with their CD4 cells not expressing the CCR5 co-recepto...
Researchers hope that by interacting with the toll-like receptor protein TLR-7 an experimental drug can help increase the immune system's ability to sense and attack HIV and HIV-infected cells.